(AGENPARL) - Rome, 20 December – Discussion, at the Ministry of Economic Development, on the problems and prospects of a sector, the pharmaceutical sector, which seems to be less affected than the others by the crisis and which focuses entirely on innovation. “It is one of the sectors – as observed by the Deputy Minister Claudius DeVincenti who presided over the meeting - which records the highest incidence on turnover of investments in research and development. We have already taken initial measures to build a favorable environment for investments in this sector and we intend to continue along this path to strengthen the attractiveness of our country”.
The entire supply chain confronted each other: from the Ministries of Health, Economy, Education and Regional Affairs to the Conference of Regions, from the Italian Medicines Agency to A.GE.NA.S (National Agency for regional health services), from Farmindustria, Assogenerici, Federchimica, to ADF, Federfarma Servizi, Federfarma to Assofarm. National trade union organizations were also present
General appreciation for the Government which, in the Stability Law, has included the Fund for innovative medicines: a sign of attention to the sector which the participants in today's Roundtable evaluated positively.
During the debate, particular attention was paid to innovative drugs (one for all, the one against hepatitis) and their entry into the market within the framework of compatibility with national health expenditure.
Strategic sector, the pharmaceutical, for the Executive: for its attractiveness in terms of investments and job opportunities. In the last year - according to Farmindustria estimates - 3000 new employees, 1600 of whom under 30 years of age.
This was announced by the Ministry of Economic Development.
Related news: Contracts, skip the chemist table for the increase knot
Big Pharma. The great challenges between “ethics and profit”
